<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224402</url>
  </required_header>
  <id_info>
    <org_study_id>FOLFIRINOX-PC-Adjuvant</org_study_id>
    <nct_id>NCT04224402</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.</brief_title>
  <official_title>Phase 2 Trial to Investigate the Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhong Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as
      postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1
      resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be treated with systemic FOLFIRINOX chemotherapy of adjusted dosage.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression Free Survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>defined as the period from the date of resection to tumor relapse caused by any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>the duration from enrollment to the patient's death (all causes)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events and severe adverse events</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>number of patients with adverse events and severity according to NCI Common Toxicity Criteria(CTC) 3.0</description>
  </other_outcome>
  <other_outcome>
    <measure>EORTC Quality of Life Questionnaire(QLQ)-C30</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Quality of life will be assessed at each study using EORTC QLQ-C30</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pancreatic Cancer Resectable</condition>
  <arm_group>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFORINOX</intervention_name>
    <description>Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.</description>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should be voluntary to the trial and provide with signed informed consent.

          2. Histologically confirmed diagnosis of pancreatic cancer

          3. Male or female, Age: 18-79 years old.

          4. No recurrence or metastasis was observed from a follow-up of 4 to 8 weeks by CT scan
             after radical surgery.

          5. the value of Carbohydrate Antigen19-9(CA19-9) &lt; 180U/mL within 12 weeks after surgery.

          6. No previous chemotherapy

          7. Eastern Cooperative Oncology Group(ECOG) performance status of 0-1

          8. normal function of organ system including the followings.

               -  No hematologic dysfunction(Platelets ≥90×10^9/L; Neutrophil ≥2×109/L;Hemoglobin
                  ≥90g/L).

               -  Serum bilirubin ≤ 1.2 × upper limits of normal(ULN); aminotransferase ≤ 5 × ULN.

               -  Serum creatinine ≤ 1.25× ULN, or creatinine clearance rate(CCR)
                  ≥60mL/min(calculated by Cockcroft-Gault formula).

          9. ECOG scored as 0-1.

         10. Life expectancy &gt; 3 months.

        Exclusion Criteria:

          1. Patient is concurrently using other antineoplastic agent.

          2. Known severe hypersensitivity to drugs in the regimen.

          3. Patient has a concurrent malignancy or has a malignancy within 5 years of study
             enrollment(with the exception of nonmelanoma skin cancer or cervical carcinoma in
             situ).

          4. Evidence of serious heart disease, including recorded history of congestive
             heart-failure, uncontrolled serious arrhythmia, angina that needs treatment of drugs,
             clinical diagnosed cardiac valve disease, history of serious myocardial infarction and
             intractable hypertension.

          5. Evidence of chronic diarrhea(≥4 times/day) or renal dysfunction.

          6. Evidence of active infection or active epidemic disease.

          7. Psychiatric illness that would prevent the patient from giving informed consent

          8. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-hong Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-hong Li, MD, Ph D</last_name>
    <phone>86-20-87343135</phone>
    <email>liyh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yu-hong Li, MD, Ph D</last_name>
      <email>liyh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Yu-hong Li, MD, Ph D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

